Medical device company DexCom (NASDAQ:DXCM) reported in Q3 2026, with sales up 11.2% year on year to $1.34 billion. The ...

Dexcom topped Wall Street’s expectations for third-quarter earnings, and the company nudged up its guidance for the remainder ...

DexCom reported third-quarter 2026 revenue of $1.34 billion, up 11% year-over-year on both a reported and organic basis, powered by a 14% jump in ...

A list of domestic and international medical and healthcare news for the past week, along with brief commentary. On October ...

Net Income and Diluted Net Income Per Share: GAAP net income was $275.1 million, or $0.72 per diluted share, for the third ...

<?xml encoding="utf-8" ?> DexCom DXCM reported third-quarter financial results on Thursday. The transcript from the company’s ...

Full-year revenue guidance moved from "$5.18 billion to $5.25 billion" in Q2 (Executive VP Sylvain, Q2) to "$5.20 billion to $5.25 billion" in Q3 (Executive VP Sylvain, Q3); Q3 also announced ...

Dexcom raised full-year revenue guidance again, to $5.20 billion to $5.25 billion, after topping expectations on both lines.

IDXX’s earnings beat estimates in each of the trailing four quarters, the average surprise being 5.7%. The Zacks Consensus Estimate for the company’s third-quarter EPS implies an increase of 9.1% from ...

Updated full-year revenue guidance of $5.20 billion to $5.25 billion passes through Q3 outperformance while factoring in approximately $5 million in incremental foreign exchange headwinds. Management ...

DexCom, Inc. reported revenue of US$1.344 billion for the third quarter ended September 30, 2026, an 11% increase from $1.209 ...

Senseonics has begun human testing of Freedom, a CGM designed to eliminate the on-body transmitter, with COO Mukul Jain ...